Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Raul Cordoba
Observed names:
R Cordoba,
Raul Córdoba,
Raúl Cordoba,
Raúl Córdoba
Institutions:
Hospital Universitario Fundación Jiménez Díaz,
Instituto de Investigación Sanitaria Fundación Jiménez Díaz
Observed institutions:
Hospital Universitario Fundación Jiménez Díaz,
Instituto de Investigación Sanitaria Fundación Jiménez Díaz
ORCID:
0000-0002-7654-8836
Observed ORCID:
0000-0002-7654-8836
OpenAlex ID:
A5121013960
Defining Cardiovascular Endpoints in Oncology Trials: Challenges and Opportunities: A Scientific Statement From the American Heart Association
2026
·
Ana Barac
, Avirup Guha
, et al.
·
Circulation
·
3
Development of lymphomatoid papulosis during brentuximab vedotin treatment: a paradoxical phenomenon
2026
·
Juan Torre-Castro
, Raúl Cordoba
, et al.
·
Leukemia & lymphoma/Leukemia and lymphoma
·
1
Cardiac Surveillance for Anthracycline Cardiotoxicity: Clinical Yield in Low-to-Intermediate Risk Patients
2026
·
Andrea Moreno-Arciniegas
, Sandra Gómez-Talavera
, et al.
·
JACC CardioOncology
Supplementary Figure S2 from Efficacy and Safety of Capivasertib (AZD5363), a Potent, Oral Pan-AKT Inhibitor, in Patients with Relapsed or Refractory B-cell Non–Hodgkin Lymphoma (CAPITAL)
2026
·
Daniel J. Hodson
, Geoffrey Shouse
, et al.
Supplementary Figure S1 from Efficacy and Safety of Capivasertib (AZD5363), a Potent, Oral Pan-AKT Inhibitor, in Patients with Relapsed or Refractory B-cell Non–Hodgkin Lymphoma (CAPITAL)
2026
·
Daniel J. Hodson
, Geoffrey Shouse
, et al.
Navigating the cardiovascular seas after allogeneic stem cell transplantation: charting a course for prevention
2026
·
Raul Cordoba
, Queralt Salas
·
European Journal of Preventive Cardiology
Validation of prognostic scores in patients with HIV ‐related diffuse large B‐cell lymphoma: The value of peripheral blood parameters—A study from the Spanish Lymphoma Group GELTAMO
2025
·
Maria Huguet
, Mireia Morgades
, et al.
·
British Journal of Haematology
PDF
Efficacy and Safety of Capivasertib (AZD5363), a Potent, Oral Pan-AKT Inhibitor, in Patients with Relapsed or Refractory B-cell Non–Hodgkin Lymphoma (CAPITAL)
2025
·
Daniel J. Hodson
, Geoffrey Shouse
, et al.
·
Clinical Cancer Research
PDF
Predictive factors and baseline risk stratification for CAR-T cell therapy-related cardiovascular toxicity
2025
·
D Farmakis
, K Karampinos
, et al.
·
European Heart Journal
Show more works
View as search
Works count:
9
Citation count:
4
H-index:
1
I10-index:
Year
Topic
Type